In this guide
Think of testing as different questions
| Question | Tools often discussed | What they cannot settle alone |
|---|---|---|
| Is further investigation warranted? | PSA, repeat PSA, risk assessment, selected blood or urine markers | These do not confirm a cancer diagnosis. |
| Where is a suspicious area? | Multiparametric prostate MRI | Not all cancers are visible on MRI. |
| Is cancer present and how aggressive does it look? | Biopsy and pathology with Gleason score / Grade Group | A biopsy samples tissue, not the entire prostate. |
| Could disease have spread? | Risk-based staging studies such as PSMA PET/CT in selected situations | Small or microscopic disease may not appear on scans. |
| Would extra biological risk information change management? | Selected tissue genomic classifiers and, when appropriate, inherited genetic testing | A single score does not replace clinical risk assessment. |
MRI and PI-RADS
Multiparametric MRI is used to identify and characterize suspicious areas, support biopsy planning and help assess disease already diagnosed. A radiology report may describe lesions using PI-RADS, a five-category scale where higher categories reflect greater suspicion for clinically significant prostate cancer.
Ask where a lesion is located, whether it has changed, and whether there are reasons for concern outside the visible area. Some tumors occur in the anterior or transition regions of the gland, where a digital rectal examination alone may not detect them. MRI can improve localization, but an MRI read as low suspicion does not guarantee the absence of important disease.
How a prostate biopsy answers a different question
A pathologist examines prostate tissue taken through a transperineal (through the skin between the scrotum and anus) or transrectal route. When MRI reveals suspicious areas, a clinician may discuss targeting those regions and sampling other parts of the gland systematically. The aim is to detect clinically meaningful cancer while reducing the chance of missing it through limited sampling.
The pathology report should identify how many cores contained cancer, how much was present, the highest Grade Group, and any additional features considered relevant. If clinical findings and pathology seem out of step, asking for explanation or an expert pathology review can be reasonable.
Gleason patterns and Grade Groups
| Grade Group | Common Gleason pattern | General meaning |
|---|---|---|
| 1 | 3+3=6 | Usually lower risk; active surveillance is often preferred when appropriate. |
| 2 | 3+4=7 | Some higher-grade pattern is present; volume and other features matter. |
| 3 | 4+3=7 | More higher-grade pattern than Group 2; risk is typically greater. |
| 4 | Gleason 8 patterns | Higher-grade cancer needing a more intensive risk discussion. |
| 5 | Gleason 9–10 | Highest-grade patterns. |
3+4 is not the same as 4+3. The predominant pattern is listed first, which is why the order matters. Other details, including the amount of pattern 4 and findings such as cribriform or intraductal patterns, can affect how clinicians interpret risk.
When genomic tests seem to disagree
Commercial tissue-based tests, such as Decipher and other classifiers, may add prognostic information in selected situations. They examine features of tumor tissue and should be interpreted alongside PSA, grade, cancer volume, imaging, stage, health status and the planned treatment. Some newer systems analyze digitized pathology images using AI.
Two methods can reach different risk categories because they use different inputs, training populations, models and endpoints. A label such as “high risk” from one test may not be measuring exactly the same outcome as an estimate from another. Ask the clinician to explain the absolute risk, time horizon and intended clinical use of each result before treating an apparent conflict as an emergency or an error.
Inherited (germline) genetic testing is a separate question: it looks for variants that may affect an individual's risk, family screening or treatment eligibility. A tumor classifier is not the same as an inherited genetic test.
The questions that help make all the reports useful
Bring these to your next consultation
- What question was each test ordered to answer?
- Which findings are established facts, and which are risk estimates?
- Do the MRI and biopsy sample the same suspicious region?
- What is the highest Grade Group, and what else matters on the pathology report?
- Would additional testing change the management choice or only add information?
- If two tests disagree, what clinical evidence is carrying the most weight?
- Would a second pathology opinion or specialist consultation be worthwhile?
Sources and further reading
These references support the general information above. Decisions about care depend on individual circumstances, and guidance can change.
Continue exploring
This independent educational article explains general information and questions to discuss with healthcare professionals. It is not a diagnosis, treatment plan or substitute for individualized care.